IDEAYA Biosciences, Inc.
IDYA
Updated: 25/09/2026, 09:08:16
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
No summaries found.
- Share price
- $36.74
- Market cap
- $3.49B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Yujiro S. Hata
- Employees
- 145
- IPO date
- 23/05/2019
- Beta
- -0.091
- Last dividend
- $0.00
- Day range
- $35.59 – $37.78
- 52-week range
- $25.36 – $42.68
- 1-day performance
- -1.92%
- 1-year performance
- 44.90%
- Current drawdown (1Y)
- -13.92%
- CIK
- 0001676725
- CUSIP
- 45166A102
- ISIN
- US45166A1025
- Created
- 07/12/2025, 04:40:35
- Last update
- 25/09/2026, 09:08:16
Track IDEAYA Biosciences, Inc. with an AI analyst
See which prediction-market events move IDYA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026
Seeking Alpha • STOCK • 11/06/2026, 05:22:42
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
PRNewsWire • STOCK • 10/06/2026, 18:05:00
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
PRNewsWire • STOCK • 09/06/2026, 00:22:00
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
PRNewsWire • STOCK • 08/06/2026, 18:01:00
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
PRNewsWire • STOCK • 01/06/2026, 13:00:00
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
MarketBeat • STOCK • 26/05/2026, 21:04:00
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
MarketBeat • STOCK • 25/05/2026, 09:07:58
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 00:00:50
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research • STOCK • 05/05/2026, 10:11:08
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
PRNewsWire • STOCK • 05/05/2026, 08:00:00
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
Seeking Alpha • STOCK • 13/04/2026, 14:11:45
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
PRNewsWire • STOCK • 13/04/2026, 08:00:00